Company / Operating Income
Crinetics Pharmaceuticals, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$516.8M
FY2025
5-year range
-$516.8M / -$107.7M
FY2021-FY2025
Trend
-52.5%
vs FY2024
Sector context
#187 of 204
Health Care
What the data says
Among 204 Health Care companies, Crinetics Pharmaceuticals, Inc. is in the bottom 8% for operating income. Operating Income has declined for 7 consecutive years, from -$6M in FY2018 to -$517M in FY2025.
Based on SEC 10-K filings.
-$517M in FY2025.
Declined from -$223M to -$517M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 204This company -$516.8M Sector average $107.7M
▼
-579.7% below sector average
Key checks
Key Insights
- Crinetics Pharmaceuticals, Inc.'s operating income has declined for 7 consecutive years.
- In FY2025, operating income decreased 52.5% year-over-year.
- Ranks #187 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$516.8M | -52.5% |
| FY2024 | -$338.9M | -52.2% |
| FY2023 | -$222.6M | -32.6% |
| FY2022 | -$167.9M | -55.9% |
| FY2021 | -$107.7M | -275.1% |
| FY2020 | -$28.7M | -214.6% |
| FY2019 | -$9.1M | -51.0% |
| FY2018 | -$6.0M | +33.8% |
| FY2017 | -$9.1M | -51.0% |
| FY2016 | -$6.0M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026